Risk Factors Update Summary
- Transitioned from owning to relying on Cell Ready for manufacturing, selling facilities and equipment.
- Completed transaction with Cell Ready, selling equipment and facilities, entering Master Services Agreement.
- Extended funding into 2025, from the fourth quarter of 2023, with substantial additional spending.
- Shifted from in-house to third-party manufacturing, evaluating additional sources for clinical and commercial supply.
- Improved manufacturing process for AML trial, reducing manufacturing time from 36 to 20 days.
- Transitioned from in-house to third-party manufacturing, facing risks of delays, quality, and quantity issues.
- Relied on Cell Ready for manufacturing, facing risks of delays, quality, and quantity issues.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1094038&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.